Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCK | P08631 | 8/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18567057 | 0.88 | HDAC1 (0.39) | HCKMAPK12MAPK14SRC | |
| SCHEMBL31086673 | 0.87 | IKBKE (0.40) | HCKMAPK12MAPK14SRCMRGPRX4 | |
| SCHEMBL17008526 | 0.87 | IKBKE (0.40) | HCKMAPK12MAPK14SRCMRGPRX4 | |
| SCHEMBL28577141 | 0.86 | HCK (0.35) | HCKMAPK12MAPK14SRCMRGPRX4 | |
| SCHEMBL31086563 | 0.86 | HCK (0.35) | HCKMAPK12MAPK14SRCMRGPRX4 | |
| SCHEMBL17008503 | 0.86 | CTSV (0.39) | HCKMAPK12MAPK14SRCKMT2A | |
| SCHEMBL17008505 | 0.86 | CTSV (0.39) | HCKMAPK12MAPK14SRCKMT2A | |
| SCHEMBL17017618 | 0.86 | FAAH (0.34) | HCKMAPK12MAPK14SRCKMT2A | |
| SCHEMBL17017129 | 0.86 | MRGPRX4 (0.40) | HCKMAPK12MAPK14SRCMRGPRX4 | |
| Hydrochloric Acid SCHEMBL17008549 | 0.85 | MRGPRX4 (0.40) | HCKMAPK12MAPK14SRCMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| EP-3418279-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS | Respivert Limited (GB) | 2018-12-26 | — | — | EP | disclosed |
| EP-3105223-B1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LTD (GB) | 2018-09-12 | — | — | EP | disclosed |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170057945-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-03-02 | — | — | US | disclosed |
| EP-3105223-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | Respivert Limited (GB) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015121660-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | MAP3K1, MAP3K2, MAP3K8 | HCK 773/4885MAPK12 43/4885MAPK14 18/4885 |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K7 | HCK 553/4885MAPK12 37/4885MAPK14 16/4885 |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | HCK 730/4885MAPK12 37/4885MAPK14 12/4885 |
| US-20170057945-A1 | NOVEL COMPOUNDS | MAPK1, MAPK6, MAPKAPK2 | HCK 2965/4885MAPK12 13/4885MAPK14 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.